Clementia Pharmaceuticals

General Information

We are a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Our lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. We are developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO) and have one registration trial and one Phase 2/3 clinical trial for two separate indications planned to commence in 2017 with data read-outs planned in 2019 and 2020.

Employees: 24
Founded: 2010
Contact Information
Address 4150 St Catherine Street West, Suite 550, Montreal, Quebec, Canada H3Z 2Y5
Phone Number (514) 940-3600
Web Address
View Prospectus: Clementia Pharmaceuticals
Financial Information
Market Cap $415.5mil
Revenues $16.6 mil (last 12 months)
Net Income $-92.8 mil (last 12 months)
IPO Profile
Symbol CMTA
Exchange NASDAQ
Shares (millions): 8.0
Price range $15.00 - $15.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Morgan Stanley/ Leerink Partners
CO-Managers Wedbush Securities/ BTIG
Expected To Trade: 8/2/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change